Bafna Pharma.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE878I01022
  • NSEID: BAFNAPH
  • BSEID: 532989
INR
143.15
-2.04 (-1.41%)
BSENSE

Dec 05

BSE+NSE Vol: 28.3 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Trident Lifeline
Gennex Lab.
Everest Organics
Bafna Pharma.
Brooks Lab.
Lyka Labs
Valiant Laborato
Nectar Lifesci.
Zim Laboratories
Amanta Healthcar
Infinium Pharma
Why is Bafna Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 8.26%
  • Poor long term growth as Operating profit has grown by an annual rate 17.34% of over the last 5 years
2
With ROCE of 5.7, it has a Expensive valuation with a 3.5 Enterprise value to Capital Employed
  • The stock is trading at a discount compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of 85.59%, its profits have risen by 980% ; the PEG ratio of the company is 0
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Bafna Pharma. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Bafna Pharma.
77.83%
1.80
43.20%
Sensex
4.83%
0.41
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
20.53%
EBIT Growth (5y)
17.34%
EBIT to Interest (avg)
4.34
Debt to EBITDA (avg)
1.53
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
1.24
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.34%
ROCE (avg)
8.44%
ROE (avg)
10.80%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
33
Industry P/E
34
Price to Book Value
4.17
EV to EBIT
34.99
EV to EBITDA
24.35
EV to Capital Employed
3.45
EV to Sales
2.66
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
5.74%
ROE (Latest)
12.46%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bullish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
PAT(Latest six months)

At Rs 6.51 cr has Grown at 189.33%

OPERATING CF(Y)

Highest at Rs 22.14 Cr

-1What is not working for the Company
NON-OPERATING INCOME(Q)

is 37.82 % of Profit Before Tax (PBT

Loading Valuation Snapshot...
Here's what is working for Bafna Pharma.
Profit After Tax (PAT) - Latest six months
At Rs 6.51 cr has Grown at 189.33%
Year on Year (YoY)
MOJO Watch
PAT trend is very positive

PAT (Rs Cr)

Operating Cash Flow - Annually
Highest at Rs 22.14 Cr and Grown
each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (Rs Cr)

Profit After Tax (PAT) - Latest six months
Higher at Rs 6.51 cr
than preceding 12 month period ended Sep 2025 of Rs 6.31 cr
MOJO Watch
In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)

Here's what is not working for Bafna Pharma.
Non Operating Income - Quarterly
is 37.82 % of Profit Before Tax (PBT)
MOJO Watch
The company's income from non business activities is high; which is not a sustainable business model

Non Operating Income to PBT